Expanding Opportunities for Specialty Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Expanding Opportunities for Specialty Excipients
China creates a potential outlet for specialty excipients as its pharmaceutical market grows.


Pharmaceutical Technology


The study describes the dissolution testing of several disintegrants and eight cationic drug actives formulated in direct-compression tablets, all prepared using a model formulation. The test disintegrants included Polyplasdone XL Crospovidone, Polyplasone XL-10 Crospovidone superdisintegrants, and the anionic disintegrants sodium starch glycolate and croscarmellose sodium. Polyplasdone XL Crospovidone and Polyplasone XL-10 Crospovidone are synthetic, insoluble, but swellable, cross-linked homopolymers of N-vinyl-2-pyrrolidone that differ only in particle size.

ISP reported that the two disintegrants (Polyplasdone XL Crospovidone, Polyplasone XL-10 Crospovidone) provide fast dissolution not only for freely soluble, cationic drug actives such as chlorpromazine hydrochloride, ranitidine hydrochloride, cetirizine hydrochloride, and venlafaxine hydrochloride, but also for cationic actives with low water solubility such as ciprofloxacin hydrochloride, fexofenadine hydrochloride, terbi-nafine hydrochloride, and clopidogrel bisulfate.

References

1. G. S. Morris and J.Huang, "China Emerges as the Next Frontier for Specialty Excipients," Pharm. Technol. 30 Technology Outlook; APIs, Intermediates, and Formulation supplement, s26–s30 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here